A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab C225 [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas
Principal Investigator
Kian Ang, MD
Status
Terminated
Date Opened To Accrual
November 22 2005
Date Closed to Accrual
March 03 2009
Date of Study Termination
May 20 2022
Disease Site
Head and Neck [HN]
Head and Neck
Phase
III
Developmental Therapeutics
No
Primary Objective
Evaluate whether the addition of cetuximab to a concurrent radiation-cisplatin regimen will improve progression-free survival in patients with locally advanced squamous cell carcinoma (SCC) of the oropharynx, hypopharynx, or larynx;
Patient Population
nSquamous cell carcinoma of the oropharynx, hypopharynx, or larynx; selected stage III-IV disease (T2N2-3M0, T3-4 any N M0)
Target Accrual
945
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.